



May 25, 2021

**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001.

**The National Stock Exchange of India Limited**  
Exchange Plaza, Bandra-Kurla Complex  
Bandra (E) Mumbai - 400 051.

Scrip code: 532531

Scrip code: STAR

Dear Madam/ Sir,

**Ref: Company's press release of March 19, 2021 titled "Stelis concludes US\$ 195m Series B and Series C fund raise - Significant interest from marquee long term.**

**Sub: Disclosure under Regulation 30 of SEBI Listing Regulations**

This has reference to the Company's press release referred above.

We now wish to inform you that Stelis has completed the **Series C round fund raising of USD 125 Million** (including secondary placement of USD 40 Million) from marquee long term investors led by TPG Growth followed by other long-term investors namely, Route One, Think Investments and the Mankekar Family.

*The funds will be used by Stelis for:*

- (a) Completion of last mile capex for the CDMO business including setting up of 6KL mammalian block, ramp up of process development lab and other technical capabilities;
- (b) Accelerating the vaccine block infrastructure with ability to cater to multiple vaccine types including viral vector, protein subunit, RNA and DNA;
- (c) Debt servicing and other general corporate purposes.

Consequent to the above transaction, Strides stake in Stelis now stands at 37.09% against 54.48% prior to the Series C funding.

Thanks & Regards,  
For **Strides Pharma Science Limited**,

**Manjula Ramamurthy**  
Company Secretary



**Strides Pharma Science Limited**

CIN: L24230MH1990PLC057062

Corp Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru - 560 076, India | Tel: +91 80 6784 0000 Fax: +91 80 6784 0700  
Regd Off: 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India | Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942  
corpcomm@strides.com, www.strides.com